Capricor Therapeutics Set to Share Financial Insights Soon

Capricor Therapeutics Financial Results Announcement

SAN DIEGO — Capricor Therapeutics (NASDAQ: CAPR), known for its groundbreaking work in biotechnology, is preparing to unveil its financial results for the first quarter ending March 31, 2025. The announcement will take place after market close on Tuesday, May 13, 2025. Following the results release, company management will host a live conference call and webcast at 4:30 p.m. ET on the same day, offering insights into the company’s trajectory and financial health.

Conference Call Details

Participants interested in joining the conference call can dial the following numbers:
Toll-Free: 1-800-717-1738
International: 1-646-307-1865
Conference ID: 73741

The event's accessibility aims to encourage stakeholders, including investors and healthcare professionals, to join and engage in discussions about the company’s future.

Live Webcast Access

For those unable to attend the live call, a replay will be available shortly after the broadcast concludes. This replay can be accessed through the company's website, ensuring that all interested parties have the opportunity to stay informed about Capricor's developments.

About Capricor Therapeutics

Capricor Therapeutics is a forefront player in biotechnology, focusing on innovative cell and exosome-based therapeutics aimed at treating rare diseases. The company’s flagship candidate, deramiocel, represents a significant advancement in cardiac-derived cell therapy, demonstrating potential benefits for patients suffering from conditions like Duchenne muscular dystrophy (DMD). With promising results from both preclinical and clinical studies, deramiocel is currently navigating late-stage development phases.

Innovative Technology Platforms

Beyond deramiocel, Capricor is expanding its horizons with proprietary technologies like the StealthX™ platform. This innovative system is in preclinical development, aiming to revolutionize how therapeutics are delivered, particularly in the fields of vaccinology and targeted therapies. The commitment to harnessing exosome technology underscores Capricor's dedication to advancing treatment methodologies for a variety of diseases.

Future Aspirations and Collaborations

Capricor’s journey involves strategic partnerships, one of which includes an exclusive agreement with Nippon Shinyaku Co., Ltd. This partnership focuses on the commercialization and distribution of deramiocel for DMD in the United States and Japan, contingent upon regulatory approval. This collaboration reflects Capricor’s commitment to bringing innovative therapies to market, enhancing their potential impact on patient care.

Media Inquiries

For additional information, media inquiries can be directed to:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204

For questions about the company’s financial outlook or corporate governance, please contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

Frequently Asked Questions

What are the upcoming financial results for Capricor Therapeutics?

Capricor Therapeutics is set to release its financial results for the first quarter of 2025 on May 13.

How can I access the live conference call?

You can join the conference call using the toll-free or international numbers provided, along with the conference ID.

What is deramiocel?

Deramiocel is Capricor’s lead product candidate, a cardiac-derived cell therapy aimed at treating Duchenne muscular dystrophy.

What partnerships does Capricor have?

Capricor has secured an agreement with Nippon Shinyaku Co., Ltd. for the exclusive commercialization of deramiocel for DMD in specific regions.

Who can I contact for more information?

For media inquiries, contact Raquel Cona; for company information, reach out to AJ Bergmann.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.